Akouos logo
Akouos AKUS

Quarterly report 2022-Q3
added 11-14-2022

report update icon

Akouos Balance Sheet 2011-2026 | AKUS

Annual Balance Sheet Akouos

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-92.9 M -55.8 M -11.3 M -23 M - - - - - - -

Long Term Debt

28.3 M - - - - - - - - - -

Long Term Debt Current

671 K 1.12 M - - - - - - - - -

Total Non Current Liabilities

- 12 M 72 M 28.1 M - - - - - - -

Total Current Liabilities

16.8 M 10.7 M - - - - - - - - -

Total Liabilities

45.1 M 22.7 M 78 M 33 M - - - - - - -

Retained Earnings

-168 M -81.7 M -33.1 M -7.38 M - - - - - - -

Total Assets

279 M 333 M 45.2 M 25.8 M - - - - - - -

Cash and Cash Equivalents

122 M 68.9 M 26.4 M - - - - - - - -

Book Value

234 M 311 M -32.8 M -7.23 M - - - - - - -

Total Shareholders Equity

234 M 311 M -32.8 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Akouos

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- 34.6 M 32 M 28.4 M 28.3 M 28.1 M 28 M 18 M 12 M 12 M 12 M 12 M 188 K 13.1 M 13.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- 44.7 M 46.6 M 47 M 45.1 M 41.2 M 40.1 M 25.1 M 22.7 M 22.7 M 22.7 M 22.7 M 19.3 M 19.3 M 19.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- -236 M -216 M -195 M -168 M -143 M -121 M -97.8 M -81.7 M -81.7 M -81.7 M -81.7 M -33.1 M -33.1 M -33.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- 226 M 245 M 256 M 279 M 297 M 317 M 322 M 333 M 333 M 333 M 333 M 45.2 M 45.2 M 45.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- 75.4 M 73.6 M 54.4 M 122 M 115 M 131 M 118 M 68.9 M 68.9 M 68.9 M 68.9 M 25.1 M 25.1 M 25.1 M - 24.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- 181 M 198 M 209 M 234 M 256 M 277 M 297 M 311 M 311 M 311 M 311 M 25.9 M 25.9 M 25.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- 181 M 198 M 209 M 234 M 256 M 277 M 297 M 311 M 311 M 311 M 311 M -32.8 M -32.8 M -32.8 M -13.1 M -7.23 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Akouos, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
$ 2.08 -14.4 % $ 214 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Altimmune Altimmune
ALT
$ 4.2 -2.67 % $ 298 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.24 -3.44 % $ 2.55 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.8 1.87 % $ 4.36 M chinaChina
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.88 -3.72 % $ 3.18 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 7.2 -1.64 % $ 1.99 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.1 2.37 % $ 356 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.35 1.46 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.37 -2.75 % $ 1.54 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
argenx SE argenx SE
ARGX
$ 756.71 -1.33 % $ 25 B niderlandNiderland
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 10.91 1.58 % $ 394 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 25.33 -6.1 % $ 3.22 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Artelo Biosciences Artelo Biosciences
ARTL
$ 1.15 -3.36 % $ 2.32 M usaUSA
Arvinas Arvinas
ARVN
$ 12.97 -2.3 % $ 920 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 61.74 -2.42 % $ 8.26 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 231.56 -0.83 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.39 -1.63 % $ 8.16 B australiaAustralia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.17 -0.85 % $ 35.2 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 4.39 -0.9 % $ 553 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 5.01 -7.47 % $ 37.5 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 14.14 -0.21 % $ 1.9 B canadaCanada
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.68 -1.75 % $ 429 M britainBritain
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.69 0.21 % $ 395 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 4.54 2.44 % $ 387 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 570.5 5.18 % $ 43.2 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 162.28 -0.98 % $ 8.07 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.56 -0.58 % $ 16.1 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA